Comprehensive Lipid Management in the Coronary Artery Disease Patient

Nivee P. Amin, Michael Blaha, Grant V. Chow, Roger S Blumenthal, Dominique Ashen

Research output: Contribution to journalArticle

Abstract

Low-density lipoprotein cholesterol (LDL-C) is the lipoprotein most implicated in atherosclerosis, and aggressive statin therapy remains the cornerstone of treatment. Adjunct therapies are often required to reach LDL-C goals, and recent studies have only fueled the debate over ezetimibe versus niacin. Alternate dosing regimens of high-potency statins can be used in those who cannot tolerate side effects. Residual risk may remain after LDL-C goals are achieved. Non-high-density lipoprotein cholesterol (non-HDL-C) must be calculated in patients with elevated triglycerides. Omega-3 fatty acids are most effective in lowering non-HDL-C. Low HDL-C levels can be raised with niacin, but clinical events may not be significantly reduced. Newer therapeutic targets, such as cholesteryl ester transfer protein (CETP) inhibitors, raise HDL-C and are being evaluated for safety and efficacy. Several ongoing, randomized controlled trials are investigating the relative efficacy of adjunctive therapies for reducing coronary heart disease events in high-risk patients.

Original languageEnglish (US)
Pages (from-to)399-406
Number of pages8
JournalCurrent Cardiovascular Risk Reports
Volume5
Issue number5
DOIs
StatePublished - 2011

Fingerprint

Coronary Artery Disease
Lipids
LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Niacin
Cholesterol Ester Transfer Proteins
Therapeutics
Omega-3 Fatty Acids
Lipoproteins
Coronary Disease
Atherosclerosis
Triglycerides
Randomized Controlled Trials
Safety

Keywords

  • Adjunct therapy
  • Atherosclerosis
  • Cholesteryl ester transfer protein inhibitor
  • Coronary heart disease
  • High density lipoprotein
  • Lipid guidelines
  • Lipid management
  • Low density lipoprotein
  • Niacin
  • Non-high density lipoprotein
  • Omega-3 fatty acid
  • Secondary prevention
  • Statin
  • Triglycerides

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Comprehensive Lipid Management in the Coronary Artery Disease Patient. / Amin, Nivee P.; Blaha, Michael; Chow, Grant V.; Blumenthal, Roger S; Ashen, Dominique.

In: Current Cardiovascular Risk Reports, Vol. 5, No. 5, 2011, p. 399-406.

Research output: Contribution to journalArticle

Amin, Nivee P. ; Blaha, Michael ; Chow, Grant V. ; Blumenthal, Roger S ; Ashen, Dominique. / Comprehensive Lipid Management in the Coronary Artery Disease Patient. In: Current Cardiovascular Risk Reports. 2011 ; Vol. 5, No. 5. pp. 399-406.
@article{c4d1f03c3d6d463d8adf29e85dd3c310,
title = "Comprehensive Lipid Management in the Coronary Artery Disease Patient",
abstract = "Low-density lipoprotein cholesterol (LDL-C) is the lipoprotein most implicated in atherosclerosis, and aggressive statin therapy remains the cornerstone of treatment. Adjunct therapies are often required to reach LDL-C goals, and recent studies have only fueled the debate over ezetimibe versus niacin. Alternate dosing regimens of high-potency statins can be used in those who cannot tolerate side effects. Residual risk may remain after LDL-C goals are achieved. Non-high-density lipoprotein cholesterol (non-HDL-C) must be calculated in patients with elevated triglycerides. Omega-3 fatty acids are most effective in lowering non-HDL-C. Low HDL-C levels can be raised with niacin, but clinical events may not be significantly reduced. Newer therapeutic targets, such as cholesteryl ester transfer protein (CETP) inhibitors, raise HDL-C and are being evaluated for safety and efficacy. Several ongoing, randomized controlled trials are investigating the relative efficacy of adjunctive therapies for reducing coronary heart disease events in high-risk patients.",
keywords = "Adjunct therapy, Atherosclerosis, Cholesteryl ester transfer protein inhibitor, Coronary heart disease, High density lipoprotein, Lipid guidelines, Lipid management, Low density lipoprotein, Niacin, Non-high density lipoprotein, Omega-3 fatty acid, Secondary prevention, Statin, Triglycerides",
author = "Amin, {Nivee P.} and Michael Blaha and Chow, {Grant V.} and Blumenthal, {Roger S} and Dominique Ashen",
year = "2011",
doi = "10.1007/s12170-011-0191-3",
language = "English (US)",
volume = "5",
pages = "399--406",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Comprehensive Lipid Management in the Coronary Artery Disease Patient

AU - Amin, Nivee P.

AU - Blaha, Michael

AU - Chow, Grant V.

AU - Blumenthal, Roger S

AU - Ashen, Dominique

PY - 2011

Y1 - 2011

N2 - Low-density lipoprotein cholesterol (LDL-C) is the lipoprotein most implicated in atherosclerosis, and aggressive statin therapy remains the cornerstone of treatment. Adjunct therapies are often required to reach LDL-C goals, and recent studies have only fueled the debate over ezetimibe versus niacin. Alternate dosing regimens of high-potency statins can be used in those who cannot tolerate side effects. Residual risk may remain after LDL-C goals are achieved. Non-high-density lipoprotein cholesterol (non-HDL-C) must be calculated in patients with elevated triglycerides. Omega-3 fatty acids are most effective in lowering non-HDL-C. Low HDL-C levels can be raised with niacin, but clinical events may not be significantly reduced. Newer therapeutic targets, such as cholesteryl ester transfer protein (CETP) inhibitors, raise HDL-C and are being evaluated for safety and efficacy. Several ongoing, randomized controlled trials are investigating the relative efficacy of adjunctive therapies for reducing coronary heart disease events in high-risk patients.

AB - Low-density lipoprotein cholesterol (LDL-C) is the lipoprotein most implicated in atherosclerosis, and aggressive statin therapy remains the cornerstone of treatment. Adjunct therapies are often required to reach LDL-C goals, and recent studies have only fueled the debate over ezetimibe versus niacin. Alternate dosing regimens of high-potency statins can be used in those who cannot tolerate side effects. Residual risk may remain after LDL-C goals are achieved. Non-high-density lipoprotein cholesterol (non-HDL-C) must be calculated in patients with elevated triglycerides. Omega-3 fatty acids are most effective in lowering non-HDL-C. Low HDL-C levels can be raised with niacin, but clinical events may not be significantly reduced. Newer therapeutic targets, such as cholesteryl ester transfer protein (CETP) inhibitors, raise HDL-C and are being evaluated for safety and efficacy. Several ongoing, randomized controlled trials are investigating the relative efficacy of adjunctive therapies for reducing coronary heart disease events in high-risk patients.

KW - Adjunct therapy

KW - Atherosclerosis

KW - Cholesteryl ester transfer protein inhibitor

KW - Coronary heart disease

KW - High density lipoprotein

KW - Lipid guidelines

KW - Lipid management

KW - Low density lipoprotein

KW - Niacin

KW - Non-high density lipoprotein

KW - Omega-3 fatty acid

KW - Secondary prevention

KW - Statin

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=84873530335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873530335&partnerID=8YFLogxK

U2 - 10.1007/s12170-011-0191-3

DO - 10.1007/s12170-011-0191-3

M3 - Article

AN - SCOPUS:84873530335

VL - 5

SP - 399

EP - 406

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 5

ER -